Jan 23 (Reuters) - Aptose Biosciences Inc APS.TO
* Will prioritize resources toward development of CG'806 for patients with FLT3-driven acute myeloid leukemia (AML)
* Will temporarily delay clinical activities with APTO-253, a Phase 1 stage compound for AML
* Company does not intend to continue to provide preliminary results in future Source text for Eikon: ID:nGNXNOALWa Further company coverage: APS.TO